Table 4.

Summary statistics for the urinary concentrations (in ng/mL) of DEHP metabolites (non creatinine-adjusted) in men from both studies separately and combined (N=850)

	Study	Geometric Mean			Selected Percentiles			P valuef
			LODa	% > LODb	10th	50th	90th
Variables
MEHP (ng/mL)
	SFF	3.7	1.2	77	0.85	3.2	17.8
	MGH	8.2	1.0	83	1.0	7.9	64.3
	TOTAL	4.9		80	0.9	4.4	39.2	< 0.001
MEHHP (ng/mL)
	SFF	23.3	0.7	99	4.6	23.7	104
	MGHc	55.6	1.3	100	13.2	47.0	272
	TOTALd	27.6		99.5	5.4	25.3	170	< 0.001
MEOHP (ng/mL)
	SFF	12.9	0.7	97	2.7	12.9	57.4
	MGHc	36.2	1.1	99	8.4	32.2	193
	TOTALd	16.1		98	3.2	15.4	110	< 0.001
MEP (ng/mL)
	SFF	206	0.8	100	31.8	205	1358
	MGH	179	1.1	100	30.2	153	1376
	TOTAL	173		100	23.6	170	1259	< 0.001
MBP (ng/mL)
	SFF	19.2	0.6	98	4.0	24.5	65.3
	MGH	17.1	0.8	97	5.1	17.7	50.8
	TOTAL	16.3		97.5	3.4	18.8	58.2	< 0.001
MBzP (ng/mL)
	SFF	11.2	0.3	98	2.1	12.5	49.8
	MGH	7.7	0.7	97	2.3	8.2	24.9
	TOTAL	8.4		97.5	1.6	9.8	41.2	< 0.001
MEHP%e
	SFF	9.4			3.9	10.1	18.8
	MGHc	9.4			3.5	10.3	24.3
	TOTALd	9.4			3.7	10.1	21.6	0.59

^aLimit of detection (LOD) in ng/mL for each phthalate metabolite.

^bPercentage of samples above the LOD for each phthalate metabolite

^cN= 221

^dN= 646

^eTo calculate MEHP%, we transformed MEHP, MEHHP and MEOHP concentrations to nanomoles per milliliter, divided MEHP levels by the sum of concentrations of MEHP, MEHHP and MEOHP, and then multiplied by 100

^fMann-Whitney U Test